- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Marylyn Donahue
Marylyn Donahue
Special Projects Editor
mdonahue@advanstar.com
Special Reports Editor Marylyn Donahue has developed and edited special interest and niche publications for the New York Daily News; Harrison and Star Inc.; Time Inc. Custom Publishing; and such Fortune 500 companies as Ford Motor Company, Sprint, Frito Lay, as well as for the Humane Society and Oxfam America. She was a special sections editor at Herald Media, an editor at Boston Magazine, columnist for the Boston Herald and staff writer for the Real Paper.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
